Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in the KIT or PDGFRA genes.
Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and would benefit from a comprehensive review of novel treatments for soft tissue sarcomas and gastrointestinal stromal tumors.
Pharmacists play a critical role in patient education, monitoring, and management of treatment-related toxicities and would benefit from a comprehensive review of novel treatments for soft tissue sarcomas and gastrointestinal stromal tumors.
Join Daniel Melzer, PharmD, BCOP from Moffitt Cancer Center for this webinar in the 2018 NCCN Pharmacy Update Webinar Series on the topic New Cytotoxic and Targeted Therapies for Soft Tissue Sarcoma.
Join Daniel Melzer, PharmD, BCOP from Moffitt Cancer Center for this webinar in the 2018 NCCN Pharmacy Update Webinar Series on the topic New Cytotoxic and Targeted Therapies for Soft Tissue Sarcoma.
This information was originally presented at the NCCN 22nd Annual Conference: Improving the Quality, Effectiveness, and Efficiency of Cancer Care™ held in Orlando, Florida, from March 23 - 25, 2017.
Interdigitating dendritic cell sarcoma (IDCS) is an extremely rare dendritic cell tumor with slightly more than 100 cases reported in the English literature.
Facebook
Twitter
LinkedIn
Forward
